Mirel Cabrera
Montevideo, MO, Uruguay
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Theranostic Radiotracers for Melanoma Imaging and Therapy: A Comparative Study of Subcutaneous and Intradermal Tumor Models Using DOTA-Re-CCMSH Peptides.
Journal: Cancer biotherapy & radiopharmaceuticals
Published: May 23, 2025
Theranostic Potential of [177Lu]Lu-DOTA-Tocilizumab in Multiple Myeloma: A Preclinical Evaluation.
Journal: Anti-cancer agents in medicinal chemistry
Published: May 21, 2025
Molecular Imaging of Melanoma VEGF-expressing Tumors through [99mTc]Tc-HYNIC-Fab(Bevacizumab).
Journal: Anti-cancer agents in medicinal chemistry
Published: April 08, 2024
Preclinical Evaluation of 99mTc-Labeled LHRH Analog as Cancer Receptor Imaging.
Journal: Oncology
Published: January 29, 2024
Enhanced Tumor Targeting of Radiolabeled Mouse/Human Chimeric Anti-Tn Antibody in Losartan-Treated Mice Bearing Tn-Expressing Lung Tumors.
Journal: Cancer biotherapy & radiopharmaceuticals
Published: January 12, 2024
99mTc Stearyl 6-(benzylidenehydrazinyl) nicotinamide Liposomes as Tumor Permeability Evaluation Tracer.
Journal: AAPS PharmSciTech
Published: January 06, 2021
Development of (177)Lu-DOTA-Dendrimer and Determination of Its Effect on Metal and Ion Levels in Tumor Tissue.
Journal: Cancer biotherapy & radiopharmaceuticals
Published: December 02, 2015
Labeling polyamidoamine (PAMAM) dendrimers with technetium-99m via hydrazinonicotinamide (HYNIC).
Journal: Current radiopharmaceuticals
Published: May 10, 2014
Showing 1-8 of 8
Last Updated: 09/26/2026